Bruker Q3 2026 Margin Expands as Non-GAAP EPS Rises 24%

Bruker Corporation (Nasdaq: BRKR) reported a sharp expansion in third-quarter 2026 non-GAAP operating margin and double-digit adjusted earnings growth, even as revenue increased only modestly. Cost savings and a more favorable business mix helped lift profitability, while weakness in parts of the BSI portfolio was offset by strong growth at Bruker Energy & Supercon Technologies.

Revenue for the quarter ended September 30 rose 1.6% year over year to $874.0 million. Organic revenue increased 0.7%, acquisitions contributed 1.7%, and foreign exchange reduced growth by 0.8%. On a constant-exchange-rate basis, revenue grew 2.4%.

Non-GAAP gross margin increased 120 basis points to 51.3%. Non-GAAP operating income climbed 34.7% to $142.6 million, and operating margin expanded 400 basis points to 16.3%. Bruker attributed about 300 basis points of that improvement to cost savings and 90 basis points to business mix.

Non-GAAP net income attributable to common shareholders rose 27.1% to $86.3 million, while non-GAAP earnings per share increased 24.4% to $0.56. On a GAAP basis, Bruker recorded a loss of $0.81 per share.

BSI softness offsets stronger BEST growth

Third-quarter organic revenue at BSI declined 0.4%, while BEST organic revenue grew 11.8%. BSI’s book-to-bill ratio remained above 1.0, indicating that bookings exceeded revenue during the period.

For the first nine months of 2026, Bruker BioSystems revenue rose by a low-single-digit percentage at constant exchange rates. Strong growth in academic medical and biopharma markets was partly offset by softness in other academic and government markets and food testing. Infrared and Raman spectroscopy posted strong revenue growth, while nuclear magnetic resonance was weaker. The acquisition of Switzerland-based TOFWERK supported solid mass spectrometry order growth.

Bruker Microbiology & Infection Diagnostics also generated low-single-digit constant-currency revenue growth year to date. The group reported strength in Europe, but softer performance in Asia-Pacific and the United States. Molecular diagnostics delivered robust revenue and order growth, while microbiology recorded modest growth.

Bruker NANO revenue declined by a low-single-digit percentage at constant exchange rates. Strength in semiconductor and biopharma markets was offset by weakness in academic and government and industrial demand. Revenue growth in the United States and Europe was counterbalanced by softer Asia-Pacific results. Bruker said orders were strong for AI-related memory and advanced-packaging semiconductor metrology tools.

BEST revenue increased 8% at constant exchange rates for the first nine months, net of intercompany eliminations. Research Instruments delivered robust growth, and superconductors posted solid gains. The segment also recorded strong order growth from multiyear contracts covering superconducting wire, fusion-energy technologies and high-energy physics tools.

Year-to-date margins and cash flow improve

Revenue for the first nine months rose 3.1% to $2.54 billion. Organic revenue declined 0.3%, with BSI down 1.0% and BEST up 8.3%. Acquisitions added 1.9% to revenue growth, while foreign exchange contributed 1.5%. Constant-exchange-rate revenue increased 1.6%.

Year-to-date non-GAAP operating margin expanded 220 basis points to 13.6%. Bruker said cost savings contributed 280 basis points and net U.S. tariffs added 60 basis points, while volume and mix reduced the margin by 50 basis points and foreign exchange created a 70-basis-point headwind.

Non-GAAP EPS for the nine-month period rose 10.6% to $1.36, including a $0.05 foreign-exchange headwind. Bruker reported a GAAP loss of $1.20 per share for the period.

Third-quarter operating cash flow improved to $118.2 million from an outflow of $33.2 million a year earlier. Non-GAAP free cash flow was $96.7 million, compared with an outflow of $54.1 million. The company attributed the improvement to higher net income excluding a non-cash goodwill impairment and better working capital.

Bruker repaid $58 million of debt during the quarter. Net debt stood at approximately $1.60 billion at September 30, and the net leverage ratio was 2.4 times. Cash, equivalents and short-term investments totaled $119.7 million.

2026 outlook incorporates updated currency assumptions

Bruker expects full-year 2026 revenue of $3.52 billion to $3.56 billion, representing reported growth of 2.5% to 3.5%. Organic revenue growth is projected at 1% to 2%, with acquisitions expected to contribute approximately 1.5%. Constant-exchange-rate revenue growth is forecast at 2.5% to 3.5%.

The company expects non-GAAP EPS of $2.10 to $2.15, equivalent to growth of 15% to 17%. Non-GAAP operating margin is projected to increase by 250 to 300 basis points. Foreign exchange is expected to have a neutral effect on revenue but reduce operating margin by about 50 basis points and EPS by approximately $0.05.

Bruker also assumes an effective tax rate of 27.5% and capital expenditures of about $110 million for the year.

The company highlighted potential uncertainty from disruptions in U.S. academic and government markets, global economic conditions, tariffs and trade-policy changes, geopolitical tensions, supply constraints, foreign-exchange movements and the execution of restructuring and cost-control initiatives. Integration risks related to acquisitions and Bruker’s ability to meet its debt obligations also remain among the factors that could cause results to differ from its outlook.